Ergotamine
Cafergot, Ergostat, Wigraine, Wigrettes (ergotamine) is a small molecule pharmaceutical. Ergotamine was first approved as Cafergot on 1982-01-01. It is used to treat cluster headache and migraine disorders in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 1D. In addition, it is known to target 5-hydroxytryptamine receptor 1F, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 6, and 5-hydroxytryptamine receptor 7.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
nervous system diseases | D009422 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Caffeine
+
Ergotamine tartrate
Ergotamine tartrate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
MEDIHALER ERGOTAMINE | 3M | N-012102 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
cluster headache | HP_0012199 | D003027 | G44.00 |
migraine disorders | EFO_0003821 | D008881 | G43 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
---|---|
J1110 | Injection, dihydroergotamine mesylate, per 1 mg |
Clinical
Clinical Trials
7 clinical trials
View more details

Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Essential hypertension | D000075222 | I10 | — | — | 1 | 1 | — | 2 | |
Healthy volunteers/patients | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Covid-19 | D000086382 | U07.1 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | ERGOTAMINE |
INN | ergotamine |
Description | Ergotamine is a peptide ergot alkaloid that is dihydroergotamine in which a double bond replaces the single bond between positions 9 and 10. It has a role as a non-narcotic analgesic, a vasoconstrictor agent, a serotonergic agonist, an alpha-adrenergic agonist, a mycotoxin and an oxytocic. It is a conjugate base of an ergotamine(1+). |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21 |
Target
Agency Approved
HTR1D
HTR1D
Organism
Homo sapiens
Gene name
HTR1D
Gene synonyms
HTR1DA, HTRL
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 1D
Protein synonyms
5-HT-1D, 5-HT-1D-alpha, 5-hydroxytryptamine (serotonin) receptor 1D, G protein-coupled, Serotonin 1D alpha receptor, Serotonin receptor 1D
Uniprot ID
Mouse ortholog
Htr1d (15552)
5-hydroxytryptamine receptor 1D (Q8BUW7)
Alternate
HTR1F
HTR1F
HTR2B
HTR2B
HTR2A
HTR2A
HTR1E
HTR1E
HTR5A
HTR5A
HTR2C
HTR2C
HTR6
HTR6
HTR7
HTR7
Variants
Clinical Variant
No data
Financial
Migergot - Horizon Therapeutics Public
$
€
£
₣

Mock data
Subscribe for the real data
Subscribe for the real data

Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:

Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,789 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cafergot, Ergomar , Migergot
Adverse Events
Top Adverse Reactions

Mock data
Subscribe for the real data
Subscribe for the real data
480 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more